Stanford Cancer Institute
Showing 581-590 of 623 Results
-
Shan X. Wang
Leland T. Edwards Professor in the School of Engineering and Professor of Electrical Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsShan Wang was named the Leland T. Edwards Professor in the School of Engineering in 2018. He directs the Center for Magnetic Nanotechnology and is a leading expert in Edge AI, biosensors, information storage and spintronics. His research and inventions span across a variety of areas including Edge AI, magnetic biochips, in vitro diagnostics, cancer biomarkers, magnetic nanoparticles, magnetic sensors, magnetoresistive random access memory, and magnetic integrated inductors.
-
Teresa Wang
Klaus Bensch Professor in Experimental Pathology, Emerita
Current Research and Scholarly InterestsThe main focus of our research is to understand how cells maintain genome integrity by checkpoint mechanisms during chromosome replication.
-
Irene Wapnir, MD
Professor of Surgery (General Surgery)
On Partial Leave from 12/16/2025 To 04/15/2026Current Research and Scholarly InterestsClinical trials in operative procedures such as Nipple-sparing mastectomy, arm lymphatic mapping, skin perfusion and Treatments for Breast Cancer, especially local recurrence. Dr. Wapnir is institutional Principal Investigator and Chair for National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Laboratory and translational research includes exploring the activity of breast iodide transporter in breast cancer brain metastasis.
-
Roger Warnke
Ronald F. Dorfman, M.B.B.ch., FRCPath, Professor in Hematopathology, Emeritus
Current Research and Scholarly InterestsAs an Emeritus Professor, I no longer have a research laboratory and am now fully retired.
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.
